WHAT IF THERE WAS AN EFFECTIVE TREATMENT?

Stayble Therapeutics’ treatment has the potential to offer an affordable, quick and simple alternative to the millions of people with cLBP who do not respond to analgesics and physiotherapy, and who are not eligible, cannot afford, or do not want to be operated.

STA363

Our treatment, called STA363, addresses instability and leakage of pain-producing molecules in degenerating disks, the core causes of chronic low back pain (cLBP), by injecting a therapeutic agent into the disc. The substance is well documented and has been used for decades in humans allowing a relatively fast, inexpensive and low-risk route to market.

The treatment in short

The STA363 treatment is a world unique, patent pending innovation to stabilise degenerated discs. Discogenic cLBP often resolves spontaneously over time as the disc becomes sclerotic and stiff, and STA363 shortens this process from decades to a few months. Instead of costly and time-consuming procedures, such as spinal fusions or long-term physiotherapy, STA363 is administered as a one-time injection. STA363 was invented by Professor Kjell Olmarker at the Institute of Biomedicine, Sahlgrenska Academy, Sweden and a phase 1b clinical trial has been successfully completed.

REMOVING THE ROOT CAUSES OF THE PAIN

By injecting a biologically active substance directly into degenerated intervertebral discs, cells are triggered to produce collagen and transform the damaged disc into connective tissue. This reduces leakage of pro-inflammatory molecules and helps re-stabilising the intervertebral segment. By stabilising the disc, the STA363 treatment has the potential to remove the root cause of the pain.

MAKING cLBP TREATMENT AVAILABLE. FOR EVERYONE.

Stayble’s treatment is intended for patients suffering from low back pain where the pain is thought to be caused by disc degeneration. Our main focus is to help people who do not respond sufficiently to conservative treatments. It is much less time consuming than physiotherapy, taking experienced radiologists and spine surgeons less than an hour to perform.

THE BENEFITS OF STA363

Currently available surgical treatments focus on different types of implants and new products in this field only modestly improve the outcome for the patient compared with older. The STA363 treatment on the other hand, is a minimally invasive, single injection of the drug into the disc. The product targets chronic low back pain by pharmacological means, in contrast to the currently available options of physiotherapy or surgery. This has many benefits for various stakeholders.

DURABLE SYMPTOMATIC RELIEF

Pain, disability and lowered quality of life is expected to be significantly reduced for patients. The treatment is presumed to be effective significantly faster than surgical intervention, last the patient’s entire life and will not require any extensive rehabilitation.

LOWER COSTS FOR PAYERS

The direct cost for a spinal fusion is currently around 20,000 USD and STA363 has the potential to lower the associated treatment costs substantially.

REACHING MORE PATIENTS

STA363 is an easy-to-use treatment allowing spine clinics to increase the number of treated patients. Patients eligible for treatment with STA363 only minimally overlap with those eligible for spinal surgery.

SOCIETAL BENEFITS

Spinal surgery is followed by months of rehabilitation and accompanying sick leave. STA363 could allow a much quicker return to a productive life.

Want to know more?

We are always looking for passionate partners and investors who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you shortly.

info@stayble.se